RAPS has released the results of its biennial survey of the global healthcare regulatory profession.
The Regulatory Affairs Professionals Society (RAPS) has released the results of its biennial survey of the global healthcare regulatory profession, which found regulatory professionals’ salaries on the rise and identified key drivers of higher compensation. The report also sheds light on regulatory professionals’ job responsibilities and backgrounds. RAPS published key survey results and analysis in its 2014 Scope of Practice & Compensation Report for the Regulatory Profession, which can be downloaded from RAPS’ website at www.raps.org/news-trends/scope-of-practice/2014.
The report shows regulatory professionals’ base salaries increased by an average of 5.4% from 2012 to 2013. Since 1999, their average base salary has grown 3.5% per year, and average total compensation, including bonuses, increased 4% per year. The average salary for a full-time, US-based regulatory professional was $126,163 in 2013.
“Regulatory knowledge and expertise has proven to be quite valuable to employers in the life sciences sector,” said RAPS Executive Director Sherry Keramidas, PhD, FASAE, CAE. “This makes good sense from a business and strategic standpoint. For drugmakers and medical device companies, regulatory setbacks can be very costly. Having skilled people to help guide products through the regulatory process is a great asset, and employers recognize that.”
The survey found regulatory professionals’ pay is affected most by job level, but also by several other related and interdependent factors, including regulatory experience, highest-earned degree, total professional experience and whether they hold the Regulatory Affairs Certification (RAC) credential. The credential has the greatest impact on compensation for professionals in the US, where the RAC has the longest history, as US-based professionals with the RAC earn 10.6% more than their peers.
The survey also asked respondents about their job responsibilities. Regulatory intelligence and regulatory strategy have grown in importance and together now represent an average of about 20% of regulatory professionals’ time. They also spend significant time on business and management duties.
More than 90% of regulatory professionals began working in another field before transitioning into regulatory; 75% worked in fields closely related to regulatory. Overall, the ratio of total professional experience to regulatory experience is nearly two to one.
Regulatory professionals are highly educated. Nearly all professionals (99%) have university degrees, and 69% pursued postgraduate studies. More than 40% hold master’s degrees and 20% have doctorates. Most regulatory professionals (94%) hold degrees in the sciences, a clinical discipline or engineering. Degrees or certificates in regulatory affairs or regulatory science are becoming more common but still are held by a minority of professionals in the field.
The 2014 Scope of Practice & Compensation Report for the Regulatory Profession is based on survey responses from 3,355 regulatory professionals in 62 countries. For a copy of the report, visit www.raps.org/news-trends/scope-of-practice/2014 or contact RAPS’ Senior Manager of Communications Zachary Brousseau at [email protected] or +1 301 770 2920, ext. 245.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.